VYLOY (zolbetuximab) in combination with chemotherapy is NOW AVAILABLE and approved for first-line treatment of eligible* adult patients with gastric or gastroesophageal junction adenocarcinoma in India

– VYLOY is the first and only CLDN18.2-targeted treatment approved in the India for adult patients with HER2 negative gastric and gastroesophageal junction (GEJ) adenocarcinoma whose tumors are CLDN18.2 positive – – Central Drugs Standard Control Organization approval was based on the global Phase 3 trials GLOW & SPOTLIGHT where the combination treatment extended median overall survival …

Breaking Into Product Management in 2026: Why Most Professionals Struggle and How to Get It Right

Product management roles are expanding as organisations prioritise product-led growth and digital transformation. Yet, readiness continues to lag. According to McKinsey & Company Project Management Index, 2025, fewer than half of product managers feel fully prepared for their roles, highlighting a critical capability gap. At the same time, Deloitte Digital Project Management 2025 report notes …